CPSE:COLO B

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Coloplast A/S develops and markets intimate healthcare products and services worldwide. More Details


Snowflake Analysis

Excellent balance sheet average dividend payer.


Similar Companies

Share Price & News

How has Coloplast's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: COLO B has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-4.0%

COLO B

-3.4%

DK Medical Equipment

-2.7%

DK Market


1 Year Return

13.6%

COLO B

25.4%

DK Medical Equipment

24.9%

DK Market

Return vs Industry: COLO B underperformed the Danish Medical Equipment industry which returned 25.4% over the past year.

Return vs Market: COLO B underperformed the Danish Market which returned 24.9% over the past year.


Shareholder returns

COLO BIndustryMarket
7 Day-4.0%-3.4%-2.7%
30 Day-6.9%-3.8%-1.7%
90 Day-13.1%-6.0%4.4%
1 Year15.9%13.6%27.0%25.4%27.3%24.9%
3 Year109.5%94.3%81.8%74.6%45.7%34.7%
5 Year95.8%72.4%126.7%108.5%57.8%38.1%

Price Volatility Vs. Market

How volatile is Coloplast's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Coloplast undervalued compared to its fair value and its price relative to the market?

50.28x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: COLO B (DKK934.6) is trading above our estimate of fair value (DKK562.59)

Significantly Below Fair Value: COLO B is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: COLO B is good value based on its PE Ratio (50.3x) compared to the DK Medical Equipment industry average (59.1x).

PE vs Market: COLO B is poor value based on its PE Ratio (50.3x) compared to the Danish market (15.9x).


Price to Earnings Growth Ratio

PEG Ratio: COLO B is poor value based on its PEG Ratio (5x)


Price to Book Ratio

PB vs Industry: COLO B is overvalued based on its PB Ratio (31.2x) compared to the DK Medical Equipment industry average (9.8x).


Next Steps

Future Growth

How is Coloplast forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?

10.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: COLO B's forecast earnings growth (10.1% per year) is above the savings rate (0.3%).

Earnings vs Market: COLO B's earnings (10.1% per year) are forecast to grow slower than the Danish market (11.6% per year).

High Growth Earnings: COLO B's earnings are forecast to grow, but not significantly.

Revenue vs Market: COLO B's revenue (7.6% per year) is forecast to grow faster than the Danish market (6.2% per year).

High Growth Revenue: COLO B's revenue (7.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: COLO B's Return on Equity is forecast to be very high in 3 years time (53.1%).


Next Steps

Past Performance

How has Coloplast performed over the past 5 years?

17.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: COLO B has high quality earnings.

Growing Profit Margin: COLO B's current net profit margins (21.3%) are lower than last year (23.4%).


Past Earnings Growth Analysis

Earnings Trend: COLO B's earnings have grown by 17.4% per year over the past 5 years.

Accelerating Growth: COLO B's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: COLO B had negative earnings growth (-4.1%) over the past year, making it difficult to compare to the Medical Equipment industry average (-51.7%).


Return on Equity

High ROE: COLO B's Return on Equity (62.1%) is considered outstanding.


Next Steps

Financial Health

How is Coloplast's financial position?


Financial Position Analysis

Short Term Liabilities: COLO B's short term assets (DKK6.5B) exceed its short term liabilities (DKK5.9B).

Long Term Liabilities: COLO B's short term assets (DKK6.5B) exceed its long term liabilities (DKK1.0B).


Debt to Equity History and Analysis

Debt Level: COLO B's debt to equity ratio (39.5%) is considered satisfactory.

Reducing Debt: COLO B's debt to equity ratio has increased from 13.2% to 39.5% over the past 5 years.

Debt Coverage: COLO B's debt is well covered by operating cash flow (192.5%).

Interest Coverage: COLO B's interest payments on its debt are well covered by EBIT (585.1x coverage).


Balance Sheet


Next Steps

Dividend

What is Coloplast current dividend yield, its reliability and sustainability?

1.82%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: COLO B's dividend (1.82%) is higher than the bottom 25% of dividend payers in the Danish market (1.34%).

High Dividend: COLO B's dividend (1.82%) is low compared to the top 25% of dividend payers in the Danish market (3.74%).


Stability and Growth of Payments

Stable Dividend: COLO B's dividends per share have been stable in the past 10 years.

Growing Dividend: COLO B's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its high payout ratio (91.5%), COLO B's dividend payments are not well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: COLO B's dividends in 3 years are forecast to be covered by earnings (85.8% payout ratio).


Next Steps

  • Explore strong dividend paying companies in the Healthcare industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

4.0yrs

Average management tenure


CEO

Kristian Villumsen (50 yo)

1.83yrs

Tenure

kr.17,500,000

Compensation

Mr. Kristian Villumsen has been the President and Chief Executive Officer of Coloplast A/S since December 4, 2018. Mr. Villumsen was an Executive Vice President of Chronic Care at Coloplast A/S since July ...


CEO Compensation Analysis

Compensation vs Market: Kristian's total compensation ($USD2.74M) is about average for companies of similar size in the Danish market ($USD3.26M).

Compensation vs Earnings: Kristian's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Kristian Villumsen
President & CEO1.83yrskr.17.50m0.043%
DKK 84.8m
Anders Lonning-Skovgaard
Executive VP & CFO6.25yrskr.9.90mno data
Allan Rasmussen
Executive Vice President of Global Operations6.25yrskr.9.50m0.00015%
DKK 298.2k
Paul Marcun
Executive Vice President of Growth1.75yrskr.8.90mno data
Thomas Barfod
Senior Controller & Director13.83yrskr.450.00k0.0019%
DKK 3.7m
Ellen Bjurgert
Vice President of Investor Relations4yrsno datano data
Dennis Kaysen
Director of Corporate Communicationsno datano datano data
Camilla Mohl
Senior Vice President of People & Culture0.17yrno datano data
Nicolai Andersen
Executive Vice President of Innovationno datano datano data
Alain Morvan
Senior Vice President of Sales Europe8.5yrsno datano data
Oliver Johansen
Senior Vice President of Global R&D7.83yrsno datano data
Rasmus Møller
Senior Vice President of Wound & Skin Care0.083yrno datano data

4.0yrs

Average Tenure

50yo

Average Age

Experienced Management: COLO B's management team is considered experienced (4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Thomas Barfod
Senior Controller & Director13.83yrskr.450.00k0.0019%
DKK 3.7m
Carsten Hellmann
Independent Director2.83yrskr.634.00k0.0028%
DKK 5.6m
Jørgen Tang-Jensen
Independent Director12.83yrskr.767.00k0.0034%
DKK 6.8m
Lars Rasmussen
Chairman of the Board1.83yrskr.20.56m0.098%
DKK 193.8m
Niels Louis-Hansen
Deputy Chairmanno datakr.910.00k22.11%
DKK 43.9b
Jette Nygaard-Andersen
Independent Director4.83yrskr.532.00kno data
Birgitte Nielsen
Independent Director4.83yrskr.634.00k0.000080%
DKK 159.0k
Nikolaj Gundersen
Director2.75yrskr.369.00k0.000070%
DKK 139.1k
Roland Pedersen
Director2.75yrskr.369.00k0.00070%
DKK 1.4m

3.8yrs

Average Tenure

57yo

Average Age

Experienced Board: COLO B's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Coloplast A/S's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Coloplast A/S
  • Ticker: COLO B
  • Exchange: CPSE
  • Founded: 1954
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: kr.198.768b
  • Shares outstanding: 212.68m
  • Website: https://www.coloplast.com

Number of Employees


Location

  • Coloplast A/S
  • Holtedam 1-3
  • Humlebæk
  • 3050
  • Denmark

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CLPB.FOTCPK (Pink Sheets LLC)YesClass B SharesUSUSDMar 1993
COLO BCPSE (OMX Nordic Exchange Copenhagen)YesClass B SharesDKDKKMar 1993
CBHDDB (Deutsche Boerse AG)YesClass B SharesDEEURMar 1993
COLOBCBATS-CHIXE (BATS 'Chi-X Europe')YesClass B SharesGBDKKMar 1993
0QBOLSE (London Stock Exchange)YesClass B SharesGBDKKMar 1993
COLOBSWX (SIX Swiss Exchange)YesClass B SharesCHCHFMar 1993
COLOWBAG (Wiener Boerse AG)YesClass B SharesATEURMar 1993
0QBO NBMV (Bolsa Mexicana de Valores)YesClass B SharesMXMXNMar 1993
CLPB.YOTCPK (Pink Sheets LLC)SPONSERED ADSUSUSDNov 2010

Biography

Coloplast A/S develops and markets intimate healthcare products and services worldwide. It provides ostomy care products, including SenSura Mio, which provides fit to individual body shapes and optimal dis ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/30 20:54
End of Day Share Price2020/10/30 00:00
Earnings2020/06/30
Annual Earnings2019/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.